We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Next Generation Diagnostic Platforms Available in Europe

By LabMedica International staff writers
Posted on 19 Feb 2009
Two next-generation clinical laboratory systems are now commercially available in Europe.

The Vitros 5600 integrated system and the high-capacity Vitros 3600 immunodiagnostic system are next generation platforms that were designed to address the needs of modern clinical labs, giving patients and clinicians high-quality and reliable test results.

The Vitros 5600 system is designed to integrate clinical chemistry and immunoassay testing and can perform more than 100 different chemistry, immunoassay, and infectious disease assays on a single, high-quality system. Individual samples are accessed independently and in parallel for chemistry and immunoassay testing. This approach optimizes turnaround time and productivity by intelligently accounting for variable sample and test mixes. In addition to its current broad menu, which includes user-defined applications, the Vitros 5600 integrated system will be able to run new tests for earlier detection of diseases.

The Vitros 3600 immunodiagnostic system is designed for medium- to high-volume labs. Three Vitros technologies are combined into a single system: Microwell technology that with enhanced chemiluminescence enables exceptional assay performance with small sample volume requirements across a broad range of diseases; MicroSensor technology that automatically performs sample quality indices checks on the immunoassay system; and Intellicheck technology that verifies analytical performance and reduces error potential by providing real-time operator notification and tracking.

The systems were developed by Ortho Clinical Diagnostics (High Wycombe, UK). David Atkins, Ph.D., vice president of Ortho Clinical Diagnostics, said, "Our mission has always been to give health professionals the highest quality tools to determine the best treatment. The introduction of the Vitros 5600 integrated system and Vitros 3600 immunodiagnostic system continues this mission with next generation instruments that have a broad, world class menu of assays and the capacity to support future high-impact tests."

Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers high quality in-vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner.

Related Links:

Ortho Clinical Diagnostics




New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroxine ELISA
T4 ELISA
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Latest Technology News

Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC